Multiparameter immunophenotypic analysis of neoplastic cells has proven to be of great help for the investigation of minimal residual disease in acute leukemias; however, its utility has not been systematically explored in B cell chronic lymphoproliferative disorders. The aim of the present study was to investigate the incidence of phenotypic aberrations in a series of 467 consecutive leukemic B cell chronic lymphoproliferative disorders through the comparison of the phenotypic characteristics of tumor vs normal peripheral blood (n = 10) and bone marrow (n = 10) B cells, in order to explore the applicability of this strategy for minimal residual disease monitoring. An additional goal of our study was to evaluate the sensitivity of multiparameter flow cytometry for the detection of minimal residual disease in leukemic B cell chronic lymphoproliferative disorders through dilutional experiments (n = 19). From the patients analyzed 382 corresponded to B cell chronic lymphocytic leukemia/small lymphocytic lymphoma (353 typical and 29 atypical); five to prolymphocytic leukemia; 13 to hairy cell leukemias; 12 to lymphoplasmacytic lymphomas; 14 to splenic marginal zone lymphomas; 22 were follicular lymphomas; and 19 mantle cell lymphomas. The following triple stainings were systematically applied to both normal and leukemic samples: FMC7/CD5/CD19, CD22/CD23/CD19, CD103/CD25/CD19, CD10/CD11c/CD19 and sIg/sIg/CD19. Overall, 98% of the leukemic B cell chronic lymphoproliferative disorders cases displayed aberrant phenotypes at diagnosis with no significant differences being found between cases analyzed in peripheral blood vs bone marrow samples. The most common types of aberrant criteria detected included asynchronous antigen expression (92%) and antigen over-expression (54%); abnormally light scatter characteristics were found in 17% of the cases. Most of the cases studied (90%) displayed four or more phenotypic aberrations. Once patients were divided according to the different diagnostic subgroups, the overall incidence of aberrant phenotypes ranged from 79 to 80% among atypical B cell chronic lymphocytic leukemia/small lymphocytic lymphoma and prolymphocytic leukemia to 97% of follicular lymphoma and 100% of typical B cell chronic lymphocytic leukemia/small lymphocytic lymphoma, hairy cell leukemia, lymphoplasmacytic lymphomas, splenic marginal zone lymphomas and mantle cell lymphomas. Based on the aberrant phenotypes detected unique four-color stainings could be built for the specific identification of aberrant phenotypes. These include CD22/CD23/CD19/CD5 and sIg/sIg/CD19/CD5 for lymphocytic leukemia/small lymphocytic lymphoma and prolymphocytic leukemia, CD103/CD25 or CD22/CD19/CD11c for hairy cell leukemia, FMC7/CD22/CD19/CD103 and sIg/sIg/CD22/CD19 for splenic marginal zone lymphomas, CD22/CD23/CD19/CD10 for follicular lymphomas and CD10/CD22/CD19/CD5 for mantle cell lymphomas. Serial dilutional experiments showed that the sensitivity level of immunophenotyping ranges between 10 −4 and 10 −5
Introduction
Several studies have shown that immunophenotypic analysis of neoplastic cells is of great help for the investigation of minimal residual disease (MRD) in acute leukemias (AL) [1] [2] [3] [4] [5] [6] [7] and multiple myeloma (MM); 8 this is mainly due to the fact that flow cytometry immunophenotyping is more sensitive than morphology in detecting residual leukemic cells and at the same time it is applicable to a high proportion of AL (75%) and MM (95%) patients. Additionally, immunophenotyping has proved to be of utility for evaluating the effectiveness of high-dose chemotherapy and for predicting relapses in both groups of diseases. 9, 10 In recent years, intensive therapies have also been introduced to the treatment of B cell chronic lymphoproliferative disorders (B-CLPD). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Thus, high-dose chemotherapy followed by allogenic or autologous stem cell transplantation as well as purine analogues and monoclonal antibodies (Mabs) are increasingly used for the treatment of patients with B-CLPD, 23 resulting in significantly higher incidences of complete remission (CR) rates as assessed by conventional techniques. However, in spite of the more profound responses observed, relapses frequently occur due to the persistence of low numbers of residual leukemic cells, which are undetectable by conventional morphology (MRD). 24 Moreover, in B-CLPD, morphology is often unable to distinguish between normal and neoplastic cells when these latter cells are present at low frequencies, which would reduce even more the sensitivity of morphology for the evaluation of response to treatment in these patients. Therefore, other techniques, more sensitive than morphology, are needed to evaluate the CR status in these patients.
Until now assessment of CR using immunophenotypic methods has been restricted to either monitoring of the surface immunoglobulin (sIg) / light chains ratio or CD5 overexpression. 25, 26 However, the sensitivity of both approaches is relatively low (discrimination of one malignant cell among 100 to 1000 normal cells: 10 −2 -10 −3 ) and not specific, frequently being hampered by the presence of normal B cells in the sample. Surprisingly, in contrast to acute leukemias, information currently available on the phenotypic aberrations displayed by leukemic cells from patients with B-CLPD is scanty and usually either based on relatively small series of patients and/or restricted to B chronic lymphocytic leukemia (B-CLL) cases. 27 Identification of such aberrant phenotypes, which would allow the distinction between normal and neoplastic B cells even when the latter are present at low frequencies, is a pre-requisite for the immunophenotypical investigation of minimal disease levels in B-CLPD.
The aim of the present study was to explore the applicability of flow cytometry immunophenotyping for the investigation of minimal disease levels in B-CLPD patients who are in morphological complete remission following high-dose chemotherapy. For this purpose we have first analyzed the incidence of aberrant phenotypes based on a series of 467 consecutive patients with B-CLPD; in a second step we have assessed the 'in vitro' sensitivity of immunophenotyping for the detection of the most commonly observed aberrant phenotypes.
Materials and methods

Patients and controls
A total of 391 peripheral blood (PB) and 76 bone marrow (BM) samples from 467 consecutive patients newly diagnosed with leukemic B cell chronic lymphoproliferative disorders (B-CLPD) were processed in our laboratory between January 1995 and April 2000. The mean age of the patients was 70 ± 11 years (range: 27 to 95 years); 288 were males and 179 females. The diagnosis of leukemic B-CLPD was based on clinical, morphologic, immunophenotypic and molecular criteria, according to the REAL and WHO classification; 28,29 the distribution of the B-CLPD patients was as follows: B chronic lymphocytic leukemia (CLL), 382 cases: 353 typical and 29 atypical; prolymphocytic leukemia (PLL), five; hairy cell leukemia (HCL), 13; lymphoplasmacytic lymphoma (LPL), 12; splenic marginal zone lymphoma (SMZL), 14; follicular lymphoma (FL), 22; and mantle cell lymphoma (MCL), 19 patients.
As controls to establish the normal B cell phenotypes, 10 PB and 10 BM samples obtained from adult healthy volunteers were analyzed (12 were male and eight female, their age ranging from 19 to 60 years).
In both the B-CLPD patients and the healthy individuals, PB and BM samples were obtained after informed consent according to the Ethics Committee of the University Hospital of Salamanca.
Immunophenotypic studies
All samples were collected in tubes containing K 3 EDTA as anticoagulant. BM samples were immediately diluted 1/1 (vol/vol) in phosphate-buffered saline (PBS). Whole BM and PB samples (approximately 2 × 10 6 cells in 100 l per test) were stained and lysed using a direct immunofluorescence technique. The following triple-stainings -fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/PE-Cyanin 5 (PE/Cy5) -were systematically used: FMC7/CD5/CD19, CD22/CD23/ CD19, CD103/CD25/CD19, CD10/CD11c/CD19 and sIg/sIg/CD19. The source of the monoclonal antibodies (Mabs) was as follows: CD5, CD10, CD11c, CD22, CD23, CD25, anti-sIg and anti-sIg were from Becton Dickinson Biosciences (San José, CA, USA); CD19 was from Caltag (San Francisco, CA, USA); FMC7 from Immunotech (Marseille, France) and CD103 from Immunoquality Products (Grö ningen, The Netherlands). Before staining, the Leukemia sIg/sIg/CD19 tests were washed twice (5 min at 540 g twice) in 4 ml of PBS in order to remove serum Ig. For staining purposes, samples were incubated for 15 min (room temperature in the darkness) in the presence of the above mentioned reagents. Afterwards, 2 ml of FACS lysing solution (Becton Dickinson Bioscences) diluted 1/10 (vol/vol) in distilled water was added to each tube and after gentle vortex, samples were incubated for another 10 min under the same conditions as those mentioned above, in order to lyse the non-nucleated red cells. Then, cells were centrifuged (5 min at 540 g) and the cell pellet washed in 4 ml of PBS. Finally, cells were resuspended in 0.5 ml of PBS until measured in a FACSort flow cytometer (Becton Dickinson Bioscences) equipped with a 15 mW argon ion laser emitting at 488 nm using the CellQuest software programe (Becton Dickinson Bioscences). In those B-CLPD patients who displayed a low proportion of B cells as well as in all normal samples, acquisition was performed in two consecutive steps in order to increase the sensitivity of the analysis. First, a total of 20 000 events corresponding to the total nucleated cells present in the sample were acquired. In the second step, acquisition through a 'live gate' drawn on the SSC/CD19
+ region in which B lymphocytes are located was performed, in order to screen for a minimum of 3 × 
Figure 1
Illustrated example of the two-step acquisition procedure used to phenotypically characterize B cells present in a peripheral blood (PB) sample from a healthy donor. Firstly, 20 000 events corresponding to the total PB cellularity were acquired (panels a and b). After drawing an acquisition region specific for CD19 B cells (panel b) a second step acquisition through a SSC/CD19
++ 'live gate' was performed (panels c to e), in order to increase the number of B lymphocytes to be analyzed. Panels d and e show the FSC/SSC and CD22/ CD23 characteristics of the gated B cells.
Leukemia
Dilutional experiments
In order to determinate the level of sensitivity of multiparametric flow cytometry immunophenotyping for the detection of neoplastic B lymphocytes when present at very low frequencies, serial dilutional experiments were performed by adding increasingly low numbers of clonal B cells obtained from selected samples from B-CLPD patients (n = 19) in normal PB or BM samples obtained from healthy subjects. For each experiment the dilution factor ranged from 1:10 1 to 1 :10 6 . Immunophenotypic studies performed for the dilutional experiments were carried out as described above using triple stainings and a two-step acquisition procedure.
Results
Immunophenotypic analysis of normal PB and BM samples
In normal samples, B lymphocytes represented 2.26 ± 1.44% in PB and 3.46 ± 2.07% in BM, of the total nucleated cells. The phenotypic features of normal PB and BM B cells are shown in Table 1 and Figure 2 . As may be seen, most normal B cells showed reactivity for FMC7, both in PB (Ͼ99%) and − B cell subset; the levels of CD11c, FMC7, CD22 and CD19 were stronger in those B cells with higher light scatter features, these cells being negative for CD10, CD23, CD5 and CD25. In PB samples, all B lymphocytes expressed either sIg or sIg; in contrast, in normal BM a subset of B cells (0.85 ± 0.67%) was negative for both sIg and sIg (Table 1 and Figure 2 ), these corresponding to CD10
+d precursor B cells. 
Incidence of aberrant phenotypes in B-CLPD
The overall incidence of aberrant phenotypes detected among the 467 patients analyzed was 98%, ranging from 79% in atypical CLL/SLL to 97% in FL and 100% in typical CLL/SLL, HCL, PLL, SMZL and MCL. Most cases (90.2%) displayed four or more phenotypic aberrations. Regarding the type of phenotypic aberration detected, 54% of the cases showed antigen overexpression, 92% asynchronous antigen expression and 17% abnormal light scatter patterns; the percentages of aberrant phenotypes referred to each diagnostic subgroup are shown in Figure 3 . Interestingly, no major differences were detected, for the different types of phenotypic aberrations, once results obtained in PB samples were compared to those derived from BM specimens, except for CD10 (positive in a subset of BM B cells 0.84 ± 0.84) and sIg expression (negative in a subpopulation of BM B lymphocytes 0.85 ± 0.67). However, for different diagnostic subgroups distinct aberrant phenotypic patterns were observed. Accordingly, antigen overexpression was the most common aberrant phenotype observed in PLL, HCL and SMZL cases (80%, 100% and 79%, respectively) ( Table 2) , while in typical CLL/SLL, LPL, FL and MCL cases the presence of asynchronous antigen expression was the most frequently detected abnormality (99%, 83%, 95% and 100%, respectively). In atypical CLL/SLL both antigen over-expression and asynchronous antigen expression were present at similar frequencies (54% and 59%, respectively).
Representative dot plots of the most characteristic aberrant phenotypes are illustrated in Figure 4 . Below we will describe in more detail the characteristic features of each type of phenotypic aberration.
Antigen overexpression:
As shown in Table 2 , upon considering each marker individually, CD5 was overexpressed in 52% of typical CLL/SLL cases, in 28% of atypical CLL/SLL and Leukemia 40% of PLL patients. By contrast, this marker was not overexpressed in any of the HCL and LPL cases, and only in a minor proportion of SMZL (13% of cases) and FL (23% of cases). Neoplastic B cells displayed abnormally high levels of CD11c in a high proportion of HCL (69%) and SMZL (29%) cases, while this marker was overexpressed in less than 7% of atypical CLL/SLL and FL cases, and less than 1% of typical CLL/SLL cases; in the remaining diagnostic subgroups, overexpression of CD11c was not detected. Interestingly, in HCL and SMZL over-expression of CD11c was frequently associated with the presence of abnormally high levels of CD19 (64% and 27% of the cases, respectively), CD22 (36% and 40%), CD103 (83% and 33%) and FMC7 (57% and 57%). Overexpression of CD25 was detected in 54% of HCL cases, while present in only a minor proportion (Ͻ10%) of typical CLL/SLL, atypical CLL/SLL, FL and MCL, and absent in PLL, LPL and SMZL. Interestingly, aberrant expression of CD103 was mainly observed in HCL and SMZL cases (92% and 36%, respectively), being the most frequently detected aberration in HCL patients. Over-expression of surface Ig light chains (sIg) (in all cases with either kappa or lambda restriction) was almost exclusive to PLL patients among whom it was present in 60% of cases (Table 2) .
Asynchronous antigen expression:
Regarding asynchronous antigen expression, the absence of sIg in CD5
CD11c
+ or CD23 + B cells was present in a significant percentage of typical CLL/SLL cases (Table 2), the incidence of these aberrant phenotypes being lower in other leukemic B-CLPD, with the exception of the CD5 + /sIg −/+d phenotype, found in around 20% of MCL patients. Likewise, reactivity for FMC7 in the absence of sIg was also detected in around 20% of both MCL and SMZL cases, 13% of typical CLL/SLL cases. An abnormally low expression of sIg in mature CD22 + B cells was detected in around 20% of HCL (23%) and SMZL (21%) patients, the incidence of this aberrant phenotype being lower + ) were detected in a minor proportion of both typical and atypical CLL/SLL patients (Ͻ8%) while not detected in the remaining B-CLPD (Table 2 ). An abnormally low reactivity for CD22 (CD22
+ or sIg + B cells was frequently observed in almost all B-CLPD groups (Table 2) . Likewise, the presence of CD22 −/+d
/CD23
+ B cells was detected in almost all typical CLL/SLL cases (98%) and in a high percentage of FL (41%) and PLL cases (40%); in contrast, this aberrant phenotype was not found in MCL and it was present in only a minor proportion of SMZL (14%) and HCL (8%) ( Table 2) .
Expression of CD11c in CD22
−/+d B cells was mainly present in typical CLL/SLL (71%). The presence of sIg in CD22 −/+d B lymphocytes was also found in an important percentage of cases (40% to 68%) in almost all diagnostic groups except SMZL and HCL patients where it was detected in 14% and 8% of cases, respectively. Co-expression of FMC7 on CD22 −/+d cells was observed in MCL (64%), FL (41%) and typical CLL/SLL (27%), while it was absent in PLL, HCL, LPL and SMZL. Finally, asynchronous expression of mature B cellassociated antigens (CD5 + aberrant phenotypes were present in around two-thirds of typical CLL/SLL cases (66% and 67%, respectively), these patterns were detected in less than 20% of atypical CLL/SLL, LPL and FL and were virtually absent in PLL, HCL and SMZL. Interestingly, in MCL only CD5 but not CD23 was present on FMC7 − B cells in 16% of the patients. Expression of CD11c on FMC7 − B cells was found to be almost restricted to typical CLL/SLL (47% of cases). Similarly, the expression of sIg on FMC7 − B cells and the presence of FMC7 − /CD10 − B lymphocytes were mainly found within typical CLL/SLL cases (40% and 67%, respectively), and in a much lower percentage of the other diagnostic groups, with the exception of FL cases, in which these aberrations were detected in around one-third of patients (32%). Other asynchronous antigen aberrations, such as the expression of CD22 on FMC7 − B cells were present at very low frequencies in all B-CLPD groups, even within typical CLL/SLL patients ( Table 2) .
Abnormal light scatter (FSC/SSC) patterns:
Regarding the FSC/SSC features, only in HCL and SMZL neoplastic B lymphocytes were abnormally high FSC/SSC values displayed as compared to those observed for normal B cells, in a high proportion of cases (85% and 57%, respectively). In the remaining disorders, the presence of aberrant (either abnormally high or abnormally low) light scatter properties were observed in a minor proportion of cases ( Table 2) .
Investigation of the 'in vitro' sensitivity of flow cytometry immunophenotyping for detection of MRD
As shown in Table 3 (and illustrated in Figure 5 
Discussion
In spite of the theoretical interest in the development of more sensitive approaches for detecting low numbers of leukemic B cells in patients with B-CLPD -particularly upon using intensive treatment strategies -and the encouraging results reported on the immunophenotypic analysis of acute leukemias, [1] [2] [3] [4] [5] [6] [7] until now no systematic study has been carried out in a large series of B-CLPD patients in order to assess the applicability and sensitivity of multiparameter flow cytometry immunophenotyping for investigation of minimal residual disease.
Information reported in the literature on the aberrant phenotypes displayed by leukemic cells from patients with B-CLPD is scanty and usually based either on CD5 over-expression or the sIg/sIg ratio; 25, 26 however, the use of either of these two phenotypic features has proved not to be sensitive enough to detect neoplastic B cells once they are present at frequencies below 10 −3 . Abnormally low CD79b expression, alone or in combination with CD20 +d and CD5 + expression has also been used as a phenotypic criterion for monitoring MRD in B-CLL. [27] [28] [29] [30] The present paper based on a large series of leukemic B-CLPD including cases other than B-CLL shows that phenotypic aberrations are present in the majority of these patients; moreover, in more than 90% of cases, leukemic B cells simultaneously displayed four or more aberrant phenotypes.
Based on our observations specific four-color combinations of monoclonal antibodies could be proposed that would identify aberrant phenotypes in virtually all cases included in each diagnostic subgroup. Accordingly, among typical CLL/SLL patients the use of a combination of monoclonal antibodies directed against the CD22, CD23, CD19 and CD5 antigens would allow identification of phenotypically aberrant B cells in almost every case. The utility of this combination is based on the high frequency of the CD22 +d /CD23 + and CD22 +d /CD5 + patterns of asynchronous antigen expression observed in B-CLL patients. These results suggest that for B-CLL, the CD22/CD23/CD19/CD5 combination could be an alternative four-color staining to that used by Rawstron et al 27 (CD19/CD5/CD20/CD79b). In a similar way, the use of these monoclonal antibodies simultaneously with the sIg/sIg/CD19/CD5 four-color staining would allow the specific identification of aberrant phenotypes in almost all PLL cases especially if combined with the analysis of the light scatter properties of the leukemic B cells, which are abnormally high in around one-fifth of PLL patients. In the majority of HCL patients (95%) neoplastic B cells show overexpression of CD103 alone or usually in combination with abnormally high levels of expression of both CD11c and CD19; this percentage would even increase if these antigens are combined with either CD25 or CD22 in a single four-color staining. The use of sIg/sIg/CD22/CD19 and FMC7/CD22/CD19/CD103 would be the two most appropriate four-color stainings in LPL and SMZL patients for the investigation of aberrant phenotypes in MRD studies, especially if they are combined, in the latter group of patients, with the analysis of the light scatter Representative dot plots of two dilutional experiments of neoplastic B cells in normal peripheral blood samples. Case 1 corresponds to a mantle cell lymphoma and case 2 to a typical B cell chronic lymphocytic leukemia. 
/CD19
+ phenotypes can be found. Therefore, the use of the CD10/CD22/CD19/CD5 four-color staining might provide a unique valuable tool for the investigation of MRD in MCL patients.
The high incidence of aberrant phenotypes detected in the present study and the marker combinations delineated for their identification would represent ideal probes for detection of MRD, however, an additional prerequisite of MRD techniques is to be sensitive enough. In order to investigate this point, 19 different dilutional experiments were performed on patients with different types of phenotypic aberrations. Our results show that, based on a two-step acquisition procedure in which specific selection of B cells is used in the latter step, multiparametric flow cytometry immunophenotyping is a highly sensitive technique for the detection of minimal numbers of leukemic B cells displaying aberrant phenotypes. In all experiments a minimum sensitivity level of 10 −4 (one aberrant B cell among 10 −4 normal cells) was reached, independently of the type of aberration explored. Moreover, it should be noted that in a significant number of cases an even higher (10 −5 ) sensitivity level was reached by this approach. Based on the applicability and sensitivity of the multiparametric flow cytometry immunophenotyping approach shown in the present study in a large series of B-CLPD patients, it could be concluded that this is a well-suited approach for the specific detection of minimal numbers of malignant B cells and hence, could help us to obtain a more precise (and early) evaluation of the effectiveness of new treatment strategies and to better assess the CR status in leukemic B-CLPD patients. In addition, this approach could also be applied to samples obtained at diagnosis in B cell non-Hodgkin's lymphomas in leukemic phase as well to leukapheresis products from B-CLPD. Despite this, it should be noted that all studies performed here on nor-mal B cells used PB and BM samples from healthy volunteers and changes in the proportion of the different normal B cell subsets observed in regenerating PB or BM following highdose chemotherapy, may exist. Such changes might affect the sensitivity and specificity of some of the criteria proposed here to accurately identify leukemic residual cells, further investigations being necessary to elucidate these questions.
In summary, in this study we show the high applicability and sensitivity of multiparameter immunophenotyping by flow cytometry for the detection of neoplastic cells in a large group of leukemic B-CLPD patients when they are present at low frequencies. For that purpose, unique four-color staining combinations of Mabs are specifically proposed for each B-CLPD disease group.
